Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a
modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary
endpoints of objective response rate, progression free survival, time to progression,
duration of response, effects on physical function, and effects on tumor progression in women
with Androgen Receptor positive breast cancer will also be assessed.